Navigation Links
CoLucid Pharmaceuticals Details Phase 3 Development Strategy for Lasmiditan to Address Major Unmet Needs in Acute Migraine Therapy
Date:9/18/2012

DURHAM, N.C., Sept. 18, 2012 /PRNewswire/ -- CoLucid Pharmaceuticals, Inc., a privately held biopharmaceutical company, has reached agreement with the Food and Drug Administration's Division of Neurology Products concerning the development strategy for lasmiditan at a recently completed End of Phase 2 meeting. Lasmiditan is a novel therapy for acute migraine and will initially be developed to address major unmet needs in two patient populations who are poorly served by currently available therapies:  1) patients with risk factors for cardiovascular disease and those with diagnosed cardiovascular disease and 2) patients who have not had adequate efficacy from triptans.  The development program will be confirmed via the Special Protocol Assessment process.

Lasmiditan is a first-in-class Neurally Acting Anti-Migraine Agent (NAAMA) designed to deliver efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapies such as triptans.  Lasmiditan is a member of a novel chemical class called "ditans" and, unlike triptans, penetrates the central nervous system (CNS) and selectively targets receptors expressed in the trigeminal pathway.  Lasmiditan does not interact with vasoconstrictor receptors on peripheral blood vessels which are activated by triptans.

CoLucid has further evaluated lasmiditan's cardiovascular profile by recently completing a Thorough QT/QTc study (TQT) titled COL MIG-105: A Randomized, Double-blind, Placebo-controlled, 4-way Crossover Study to Compare the Effects on the Cardiac De- and Re-polarization Duration as well as other Cardiac Safety Parameters of Two Doses of Oral Lasmiditan (100 mg and 400 mg) with those of Moxifloxacin (400 mg) and Placebo in Healthy Subjects.  The statistical evaluation of the primary variable revealed that lasmiditan caused no significant QT prolongation either at 100 mg (the putative therapeutic dose) or at 400 m
'/>"/>

SOURCE CoLucid Pharmaceuticals, Inc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Sept. 17, 2014  Aratana Therapeutics, Inc. (NASDAQ: ... on licensing, developing and commercializing innovative biopharmaceutical products ... its public offering of 4,500,000 shares of its common stock ... per share. Aratana has granted the underwriters a ... 675,000 shares of its common stock. ...
(Date:9/17/2014)... Cardiac Dimensions ® , Inc. today announced ... II clinical trial of its enhanced CARILLON Mitral ... mitral regurgitation, functional improvement, quality of life and ... data, which was consistent with previous trials of ... 26 th annual Transcatheter Cardiovascular Therapeutics Conference ...
(Date:9/17/2014)... , Sept. 17, 2014  Neuraltus Pharmaceuticals, Inc. announced ... 2 clinical program of NP001 for the treatment of ... disease) are being highlighted today in an oral presentation ... Group , being held in Bloomington, Minnesota ... hoc  analysis, administration of a high dose of NP001 ...
Breaking Medicine Technology:Aratana Therapeutics, Inc. Announces Pricing of Public Offering 2Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 2Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 3Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 3
... Texas, Sept. 26, 2011 Vermillion, Inc. ... today announced the appointment of Donald Munroe, Ph.D. as ...  He will be responsible for furthering development of Vermillion,s ... continue the preclinical studies and initiate appropriate clinical studies ...
... SAN DIEGO, Sept. 26, 2011 Elevation Pharmaceuticals, Inc., ... aerosol therapies for patients with respiratory diseases, today announced ... and Chief Business Officer and Pravin Soni, PhD, as ... created positions. The company also announced that it drew ...
Cached Medicine Technology:Vermillion Enhances Management Team With A Key Addition 2Vermillion Enhances Management Team With A Key Addition 3Vermillion Enhances Management Team With A Key Addition 4Elevation Pharmaceuticals Strengthens Management Team with Appointment of Executives 2Elevation Pharmaceuticals Strengthens Management Team with Appointment of Executives 3
(Date:9/17/2014)... 17, 2014 (HealthDay News) -- A blood test that ... doctors with a better assessment of the state of ... If used routinely, this blood test could reveal when ... actually begins promoting tumor growth, the researchers suggested. ... patients with advanced prostate cancer and often initially very ...
(Date:9/17/2014)... this month for the November elections, one of the ... out the chamber door will be the Sustainable Growth ... of 2014. In a new commentary in the journal ... he and other advocates saw as the merits of ... Medicare pays doctors will return for the next Congress, ...
(Date:9/17/2014)... (PRWEB) September 18, 2014 Many countries ... influenza, instead of immunizations. The total number of poultry ... difficult to control, will result in huge losses. Therefore, ... avian influenza vaccines. , Avian influenza vaccines have been ... poultry farms in China began to use H5N1 avian ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Smart Flour ... Picks by Progressive Grocer, a leading trade magazine targeted ... awarded for originality and flavor, among other attributes. Smart ... an Editor’s Pick in the September print issue of ... website. , The pizza won based on its superior ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 A petition ... ) in laparoscopic hysterectomies and other gynecological surgeries has ... to figures posted on Change.org, at least 84,908 supporters ... , According to a recent report from ABC News, ... by Dr. Hooman Noorchashm, after his wife, Dr. Amy ...
Breaking Medicine News(10 mins):Health News:DNA Blood Test Might Identify Status of Prostate Cancer 2Health News:Failed Medicare payments law remains relevant 2Health News:Failed Medicare payments law remains relevant 3Health News:China Avian Influenza Vaccine Industry 2014-2018 Research Report Now Available at LifeScienceIndustryResearch.com 2Health News:China Avian Influenza Vaccine Industry 2014-2018 Research Report Now Available at LifeScienceIndustryResearch.com 3Health News:Smart Flour Foods Wins 2014 Progressive Grocer Editor’s Pick Award 2Health News:Power Morcellator Petition Nears 85,000 Signatures, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Petition Nears 85,000 Signatures, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Petition Nears 85,000 Signatures, Bernstein Liebhard LLP Reports 4
... American Associations for Dental Research announced that its Journal ... Five-Year Scientific Impact Factor (SIF) from 4.195 to 4.389. In ... #1 in Article Influence. This news comes from the new ... Journal Citation Reports (JCR). This latest report also shows that ...
... researchers from Boston University School of Medicine (BUSM) and ... high rate of thyroid function testing in pregnant women. ... the Journal of Clinical Endocrinology & Metabolism , ... testing on pregnant women, approximately 80 percent of cases ...
... has discovered in young adult mice that a lone brain stem ... to specialized neurons and glia important types of brain cells ... new brain stem cells. A report on their study appears ... that the brain has the capacity to generate both neurons, which ...
... HealthDay Reporter , THURSDAY, June 30 (HealthDay News) -- The ... rooms for drinking-related injuries doubles over the July 4th weekend, ... sends a daily average of nearly 1,000 youth under 21 ... problems related to alcohol use, according to a report by ...
... Italy, 30 June 2011 Differences in male and female ... be more verbally fluent, have better manual dexterity and are ... the other hand often take less time parking their cars ... new city. The latter capacities, in which men tend to ...
... Insomnia is the most prevalent sleep disorder, affecting ... the United States on a weekly basis. ... ever, randomized, controlled clinical research study in the country ... Optimization is a non-invasive technology that helps the brain ...
Cached Medicine News:Health News:Journal of Dental Research increases its scientific impact factor 2Health News:BMC conducts high rates of thyroid testing in pregnant women, study finds 2Health News:Nervous system stem cells can replace themselves, give rise to variety of cell types, even amplify 2Health News:July 4 Weekend Dangerous for Underage Boys Who Drink: Report 2Health News:Sound localization at cocktail parties is easier for men 2Health News:Wake Forest Baptist conducts clinical study for insomnia using new technology 2
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medicine Products: